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BRIEF COMMUNICATION
Platelet Quiescence in Patients With Acute 
Coronary Syndrome Undergoing Coronary 
Artery Bypass Graft Surgery
Kiran Sarathy , MBBS; George A. Wells, PhD; Kuljit Singh, MBBS; Etienne Couture, MD; Aun Yeong Chong , MD; 
Fraser Rubens , MD; Marie Lordkipanidzé , PhD; Jean- François Tanguay , MD; Derek So , MD
BACKGROUND: The optimal antiplatelet strategy for patients with acute coronary syndromes who require coronary artery 
bypass surgery remains unclear. While a more potent antiplatelet regimen will predispose to perioperative bleeding, it is 
hypothesized that through “platelet quiescence,” ischemic protection conferred by such therapy may provide a net clinical 
benefit.
METHODS AND RESULTS: We compared patients undergoing coronary artery bypass surgery who were treated with a more po-
tent antiplatelet inhibition strategy with those with a less potent inhibition through a meta- analysis. The primary outcome was 
all- cause mortality after bypass surgery. The analysis identified 4 studies in which the antiplatelet regimen was randomized 
and 6 studies that were nonrandomized. Combining all studies, there was an overall higher mortality with weaker strategies 
compared with more potent strategies (odds ratio, 1.38; 95% CI, 1.03– 1.85; P=0.03).
CONCLUSIONS: Our findings support the concept of platelet quiescence, in reducing mortality for patients with acute coronary 
syndrome requiring coronary artery bypass surgery. This suggests the routine up- front use of potent antiplatelet regimens in 
acute coronary syndrome, irrespective of likelihood of coronary artery bypass graft.
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Patients with acute coronary syndrome (ACS) ben-efit from antiplatelet therapy, including platelet P2Y12 receptor inhibitors and glycoprotein IIb/IIIa 
inhibitors; however, in subgroups requiring coronary 
artery bypass graft (CABG) surgery, no dedicated ran-
domized study exists. The concept of “platelet quies-
cence,” the hypothesis of the benefit of residual platelet 
inhibition extending to the time of CABG and confer-
ring ischemic protection, is long- standing.1 Clinically, 
this possible benefit must be balanced against the 
risk of antiplatelet drugs predisposing to perioperative 
bleeding and its sequelae. To explore the hypothesis 
of more potent platelet inhibition providing net clinical 
benefit, we conducted a systematic review and meta- 
analysis of studies of all antiplatelet agents involving 
patients admitted with ACS who underwent CABG. To 
establish overall balance of ischemic versus bleeding 
risk, we compared those treated with a more potent 
platelet inhibition strategy with those with a less potent 
inhibition to determine effects on all- cause mortality.
METHODS
A search strategy, using Ovid MEDLINE, EMBASE, 
Cochrane, Google Scholar, and PubMed databases, 
included the following search terms: platelet inhibi-
tor, ADP antagonist, P2Y12 inhibitor, ticagrelor, clopi-
dogrel, aspirin, prasugrel, glycoprotein IIb/IIIa inhibitor, 
mortality, death, major adverse cardiovascular events, 
coronary artery bypass, and acute coronary syndrome. 
No limit to the start date was applied, with the search 
conducted up to April 1, 2019. Studies were included 
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if there was documentation of all- cause mortality rate. 
We included comparative studies of case- control de-
sign (randomized control trials and observational stud-
ies). Only studies with ≥10 patients were considered 
eligible. Inclusion was restricted to publications in the 
English language or when translation of the foreign 
language publications was provided. When data were 
reported from overlapping study samples (eg, multiple 
publications from the same group), the most recent 
study or the one with the highest number of patients 
was included in the analysis. Single case reports and 
previous systematic reviews were not included. Studies 
that included multiple antiplatelet agents in 1 arm and 
compared them with a single antiplatelet strategy were 
excluded. We hand searched the references cited in the 
previous reviews and important articles. Two authors 
(K.S. and D.S.) screened titles and abstracts indepen-
dently, followed by full- text review and data extraction 
from selected studies using a standardized, pilot- 
tested extraction template. The following data were 
extracted: study characteristics (author, country, study 
design, study population, number of participants, and 
objective of the study), participant characteristics (age 
and sex), clinical characteristics (acute coronary syn-
drome, type of antiplatelet use, type of glycoprotein IIb/
IIIa inhibitor use, and whether it was a substudy of ran-
domized trial or not), 30- day mortality, and major ad-
verse cardiovascular end points. The primary outcome 
of the study was all- cause mortality. Risk estimates are 
presented using odds ratios (ORs; calculated using 
raw frequency data), with 95% CI. Heterogeneity be-
tween studies was assessed by a combination of the 
I2 point estimate, Cochran’s Q test, and observation 
of the data for each outcome. To obtain meta- analytic 
ORs and 95% CIs, a random- effects model using num-
ber of events and total sample size was used, which 
provides more conservative results than a fixed- effects 
model and assumes that each sample comes from a 
different population and that the effects in these popu-
lations may also differ. In cases of heterogeneity (de-
fined as I2 >40%), random- effects models were used. 
The reported P values are 2- tailed, with continuity cor-
rection. Significant interaction between variables was 
considered when P value was <0.05. All calculations 
were performed using Review Manager software, ver-
sion 5.2. The authors declare that all supporting data 
are publicly available or within the article. No patient- 
level data were used, and all original studies included 
in the meta- analysis had local ethics approval.
RESULTS
There was good interrater agreement with a Cohen’s 
kappa of 0.811 (95% CI, 0.46– 1.00). Although not unex-
pected, there were no studies in which the antiplatelet 
regimen was randomized after patients were found 
to require CABG. The analysis identified 4 studies1– 4 
in which the antiplatelet regimen was randomized 
and 6 studies5– 10 in which they were nonrandomized 
(Figure). Notably, for the 4 randomized controlled trials, 
the groups being compared for the present study are 
subgroups of the patients in the randomized controlled 
trial and not randomized within themselves across the 
2 subgroups. Consequentially, all the identified stud-
ies were essentially observational studies. Grouped by 
a more potent antiplatelet strategy as the intervention 
arm, there were 2 studies using glycoprotein IIbIIIa in-
hibitors versus aspirin,1,7 4 studies using clopidogrel 
versus aspirin,3,5,8,9 and 4 using novel P2Y12 inhibi-
tors (ticagrelor or prasugrel) versus clopidogrel.2,4,6,10 
Analysis of the nonrandomized studies showed a di-
rectional trend toward increased mortality with weaker 
antiplatelet strategies (OR, 1.11; 95% CI, 0.8– 1.54; 
P=0.54); analysis of the randomized trials showed that 
strategies with weaker antiplatelet effects were as-
sociated with an increase in mortality (OR, 1.79; 95% 
CI, 1.14– 2.81; P=0.01). Combining all studies (Figure), 
there was an overall higher mortality with weaker strat-
egies compared with more potent strategies (OR, 1.38; 
95% CI, 1.03– 1.85; P=0.03).
DISCUSSION
Our meta- analysis demonstrates that more potent 
antiplatelet inhibition when compared with a weaker 
antiplatelet strategy before CABG reduces mortality in 
patients with ACS. Conceptually, this supports the no-
tion that inducing platelet quiescence results in overall 
clinical benefit. Mechanistic explanations include early 
pacification of plaque rupture in preventing thrombotic 
sequelae, increased graft patency, and decreased 
platelet activation during cardiopulmonary bypass.11 
For ticagrelor, its fast offset and reversibility may in-
crease platelet availability postoperatively to minimize 
bleeding. With respect to glycoprotein IIb/IIIa inhibi-
tors, fibrinogen binding also preserves platelet function 
postoperatively.12
Importantly, antiplatelet therapies (except aspirin) 
in these studies were stopped before CABG. Current 
guidelines recommend ideal withdrawal of clopido-
grel or ticagrelor for 5 days and prasugrel for 7 days 
before CABG, predicated upon the stated intervals in 
randomized studies in which the drugs were studied, 
which in turn were based on drug pharmacokinetics. 
It is notable that in the PLATO (Platelet Inhibition and 
Patient Outcomes) trial’s surgical cohort, there appears 
to be a mortality benefit for ticagrelor over clopidogrel 
among patients with discontinuation between 1 and 
4 days before CABG, when ticagrelor- mediated plate-




 http://ahajournals.org by on February 22, 2021
J Am Heart Assoc. 2021;10:e016602. DOI: 10.1161/JAHA.120.016602 3
Sarathy et al Platelet Quiescence Pre- CABG
for those with CABG beyond 4  days, but only 20% 
of patients underwent surgery within 48  hours after 
the last dose of ticagrelor.2 This observation is further 
evidence in support of the benefits of early platelet 
quiescence and brings forth the clinical dilemma of 
the optimal timing between antiplatelet cessation and 
CABG. Indeed, the ability to perform earlier revascu-
larization and avoidance of a guideline suggested that 
a 5- to 7- day delay in ACS may be a significant fac-
tor in mortality reduction. The ongoing RAPID CABG 
(Timing of Coronary Artery Bypass Surgery Among 
Patients With Acute Coronary Syndromes Initially on 
Ticagrelor) randomized trial where patients with ACS 
are randomized to early (2– 3  days) versus delayed 
(5– 7 days) CABG after ticagrelor discontinuation (Clini 
catri als.gov, NCT02668562) will further elucidate the 
safety and potential benefits of antiplatelet therapy in 
this setting.
A limitation of our study is that the antiplatelet regi-
men from the studies were not randomized uniquely on 
the basis of patients requiring CABG. Not surprisingly, 
however, there are no studies in which patients were 
randomized when the need for surgery was known. 
Finally, ORs were calculated from raw frequency data 
for mortality, as adjusted mortality data were not avail-
able for all studies.
CONCLUSIONS
Taken collectively, our meta- analysis supports the con-
cept of platelet quiescence in reducing mortality for 
patients with ACS requiring CABG. Hence, these data 
support the routine up- front use of potent antiplatelet 
regimens in ACS, irrespective of likelihood of CABG. 
Future data may further provide guidance on optimal 
timing of CABG in these scenarios.
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Figure Forest plot of all- cause perioperative mortality among patients with acute coronary syndrome undergoing coronary 
artery bypass graft surgery assigned to stronger vs weaker antiplatelet regimens.
The blue marker represents the hazard ratio estimate for the study. The box around the marker corresponds to the weight of study in 
the random- effects model. The diamond- shaped box is the summary estimate from the random- effects model. The horizontal black 
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